Current clinical cardiovascular practice requires a clinician to have a strong foundation in multiple aspects of pharmacology. Modern cardiovascular regimens are complex, and optimal management, application of evolving guidelines, and adoption of new therapies build off a more basic understanding of pharmacokinetics and pharmacodynamics. In addition, it is likely time to add a third pillar into this discussion, the expanding field of pharmacogenomics referring to the genetic influences on drug response. This field has increasing applications in medicine and clearly holds significant promise for cardiovascular disease management. Awareness of pharmacogenomic advances and the fundamentals of pharmacokinetics and pharmacodynamics can help the clinician more easily deliver great care. Here we attempt to briefly summarize and simplify key concepts of pharmacokinetics, pharmacodynamics, and pharmacogenomics relevant to the cardiovascular disease practitioner.
JungSYChoiNKKimJY. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology. 2011;77(13):1229–1234.
2.
Dorffler-MellyJdeJongeEPontAC. Bioavailability of subcutaneous low-molecular weight heparin to patients on vasopressors. Lancet. 2002;359(9309):849–850.
3.
BerkowitzDDrollMNLikoffW. Malabsorption as a complication of congestive heart failure. Am J Cardiol. 1963;11:43–47.
WilkensonGR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–2221.
6.
BuxtonIOBenetLZ. Chapter 2. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. In: BruntonLLChabnerBAKnollmannBC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12e; 2011. Retrieved May 27, 2015 fromhttp://accessmedicine.mhmedical.com/content.aspx?bookid=374&Sectionid=41266207.
7.
DeptaJPLenziniPALanfearDE. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2015;15(1):20–25.
8.
JerlingMHuanBLLeungKChuNAbdallahHHusseinZ. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422–433.
9.
ArbelYBiratiEYFinkelsteinA. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol. 2013;36(6):342–346.
10.
WedemeyerRSBlumeH. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–211.
11.
HalperinJLHankeyGJWojdylaDM. Efficacy and Safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130(2):138–146.
12.
StangierJTahgenKStahleHMazurD. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–268.
13.
JernbergTPayneCDWintersKJ. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166–1173.
14.
StoreyRFHustedSHarringtonRA. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852–1856.
15.
WiviottSDBraunwaldEMcCabeCH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
16.
WallentinLBeckerRCBudajA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
17.
CresKRHicksJKPuiCHRellingMVEvansWE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4)467–475.
FrazerKABallingerDGCoxDR. International HapMap consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–861.
20.
LehmannHRyanE. The familial incidence of low psuedocholinesterase level. Lancet. 1956;271(6934):124.
ShuldinerARO’ConnellJRBlidenKP. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857.
23.
TangXFWangJZhangJH. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(5):1103–1112.
24.
GiustiBGoriAMMarcucciR. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103(6):806–811.
25.
ZangJHTangXFZhangY. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. Thromb Res. 2014;134(5):970–975.
26.
HochholzerWRuffCTMesaRA. Variability of individual platelet reactivity over time in patients treated with clopidogrel. J Am Coll Cardiol. 2014;64(4):361–368.
27.
MegaJLHochholzerWFrelingerAL. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–2228.
28.
KimmelSEFrenchBKasnerSE. The COAG investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293.
29.
SEARCH Study Collaborative Group, BowmanLArmitageJBulbuliaRParishSCollinsR. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007;154(5):815–823.
30.
VooraDShahSHSpasojevicI. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–1616.
31.
JohnsonJACavallariLH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharm Rev. 2013;65(3):987–1009.
